粪便细菌疗法
医学
小肠细菌生长过度
重症监护医学
肠易激综合征
胃肠病学
生物
艰难梭菌
微生物学
抗生素
出处
期刊:PubMed
日期:2022-09-25
卷期号:25 (9): 747-756
被引量:2
标识
DOI:10.3760/cma.j.cn441530-20220725-00324
摘要
Fecal microbiota transplantation (FMT) is to transplant the functional intestinal bacteria from human feces into the intestinal tract of patients, reconstruct the new intestinal flora and treat intestinal and extra-intestinal diseases. During the past 10 years, FMT has made a breakthrough in the treatment of intestinal and extra-intestinal diseases, and provided a brand-new strategy to the treatment of intestinal and extra-intestinal diseases. In view of the fact that FMT lacks a unified clinical management standard at home and abroad, relevant regulations and policies still need to be improved, and clinical application experience still needs to be accumulated, the National Institute of Hospital Administration, National Health Commission commissioned a clinical FMT expert working group to organize experts in related fields. Based on thorough analysis of relevant literature, policies and norms internationally, as well as the mature experience of FMT in many medical institutions in China, an expert consensus for clinical management of FMT in medical institutions is compiled to further strengthen its clinical application and standard management, so as to improve the safety and efficacy of FMT.肠道菌群移植(FMT)是将健康人粪便中的功能肠道菌群移植到患者肠道内,重建新的肠道菌群,实现肠道及肠外疾病的治疗。近十年来,FMT在治疗肠道内和肠道外疾病中取得了突破性的进展,给肠道内和肠道外疑难疾病的治疗带来了颠覆性的新策略。鉴于FMT在国内外缺乏统一的临床管理标准,并且存在相关法规和政策还有待完善、临床应用经验尚需积累等诸多问题,国家卫生健康委员会医院管理研究所委托临床FMT专家工作组,组织了相关领域的专家,在充分检索国内外相关文献和分析行业政策及相关制度、以及结合国内多家医疗机构开展FMT较为成熟经验的基础上,编写了适用于医疗机构开展FMT临床管理的中国专家共识,以进一步加强临床应用、规范管理和提高FMT治疗安全性和有效性。.
科研通智能强力驱动
Strongly Powered by AbleSci AI